Adare Pharma Solutions is investing at least $16.8 million to relocate its headquarters to PA from New Jersey and upgrade its two current Philadelphia facilities.
 
Governor Josh Shapiro announced the Commonwealth of Pennsylvania is investing nearly $3 million in Adare Pharma Solutions to support the life sciences company’s growth and headquarters relocation to Pennsylvania from New Jersey. Within three years, Adare’s $16.8 million expansion will create at least 115 new jobs and retain 200 existing Pennsylvania jobs.
 
Adare received a funding proposal from the Department of Community and Economic Development (DCED) for a $2.4 million Pennsylvania Industrial Development Authority (PIDA) loan, a $460,000 Pennsylvania First grant, and a $100,000 workforce development grant to train workers.
 
Adare is expanding its two Philadelphia manufacturing and packaging facilities ― a 175,000-sq.-ft. facility at 7722 Dungan Road and a 128,000-sq.-ft. facility at 1100 Orthodox Street. The company’s headquarters is being relocated from New Jersey to the Dungan Road location.
 
“I believe Pennsylvania is the best state in the nation for companies who want to innovate, grow, and succeed so I’m thrilled that Adare has chosen Pennsylvania for its headquarters and continued growth,” said Governor Josh Shapiro. “Pennsylvania is a leader in biotech and life sciences – with a talented workforce, access to key markets, and significant laboratory infrastructure – and Adare’s growth here will build on that legacy while creating more opportunity for Pennsylvanians. Pennsylvania is open for business and I look forward to welcoming more companies to our Commonwealth in the near future.”
 
“We are thrilled to announce the relocation of Adare’s global headquarters to Philadelphia,” said Tom Sellig, CEO, Adare Pharma Solutions. “This decision showcases the efforts of both Pennsylvania and Philadelphia in becoming an important life sciences hub for companies like Adare. It is crucial for us to have access to a highly skilled talent pool and key markets, and the Philadelphia area provides exactly what we need.”
 
The global technology-driven contract development and manufacturing organization (CDMO) provides end-to-end integrated services, with expertise focusing on oral dosage forms for the pharmaceutical industry. The company has seven facilities in the U.S. and Europe and has developed and manufactured more than 65 products sold by customers worldwide.